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Abstract
Rationale: Evidence-based medicine (EBM), the dominant approach to assessing the
effectiveness of clinical and public health interventions, focuses on the results of
association studies. EBM+ is a development of EBM that systematically considers
mechanistic studies alongside association studies.
Aims and objectives: To explore examples of the importance of mechanistic evidence
to coronavirus research.
Methods: We have reviewed the mechanistic evidence in four major areas that are
relevant to the management of COVID-19.
Results and conclusions: (a) Assessment of combination therapy for MERS highlights
the need for systematic assessment of mechanistic evidence. (b) That hypertension is a
risk factor for severe disease in the case of SARS-CoV-2 suggests that altering hyperten-
sion treatment might alleviate disease, but the mechanisms are complex, and it is essen-
tial to consider and evaluate multiple mechanistic hypotheses. (c) Confidence that public
health interventions will be effective requires a detailed assessment of social and psy-
chological components of the mechanisms of their action, in addition to mechanisms of
disease. (d) In particular, if vaccination programmes are to be effective, they must be
carefully tailored to the social context; again, mechanistic evidence is crucial. We con-
clude that coronavirus research is best situated within the EBM+ evaluation framework.
K E YWORD S
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1 | INTRODUCTION
Evidence-based medicine (EBM) provides the dominant approach to
assessing the effectiveness of clinical and some public health
interventions. In order to assess whether an intervention A results in
outcome B, EBM relies heavily on what we shall call “association stud-
ies,” which measure A and B to assess whether they are probabilisti-
cally dependent, conditional on potential confounders, which are
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often measured at the same time. Not all association studies are equal,
for example, experimental studies such as randomized controlled trials
(RCTs) are favoured over observational studies, ceteris paribus. Stud-
ies other than association studies tend to be regarded as less useful
by EBM. For example, mechanistic reasoning, which appeals to fea-
tures of the mechanisms by which the intervention is hypothesized to
lead to the outcome and to the mechanistic studies that investigate
these features, is viewed as inferior to association studies by present-
day EBM.1
EBM+ is a development of EBM that treats mechanistic studies
on a par with association studies.2 Figure 1 portrays the EBM+ view
of the assessment of a causal claim. Association studies provide direct
evidence that the putative cause A and the putative effect B are cor-
related (pathway C1 in Figure 1). But correlation is insufficient for cau-
sation: a correlation may be attributable to chance, bias, uncontrolled
confounders, inappropriately controlled colliders, or relationships
other than causation. What distinguishes correlations that are causal
from those that are spurious is the existence of a mechanism complex,
by which instances of A explain instances of B. So, in order to estab-
lish causation, one needs to establish the existence of a mechanism
(or mechanisms) of action as well as the existence of a correlation.
Experimental studies such as RCTs are valuable precisely because
they can indirectly support the existence of a mechanism (channel C2),
by making confounding and bias less likely to corrupt the relationship
between the dependent and independent variables. But mechanistic
studies also provide evidence of the existence of a mechanism, by
confirming or disconfirming specific hypotheses about features of the
mechanism complex linking A and B (channels M1 and M2). (In some
cases, these features can also support or undermine the claim that A
and B are correlated—channel M3.) Reasoning that proceeds along
channels M1, M2, and/or M3 is mechanistic reasoning. Mechanistic
reasoning is particularly pertinent when specific hypotheses about
key features of the mechanism complex are established (or ruled out)
by mechanistic studies (see Section 3).
Given this more nuanced picture of causal assessment, it can be
important to explicitly and systematically scrutinize mechanistic stud-
ies when assessing causal claims. This need is now often recognized
when assessing the effects of environmental exposures4 but less so
when assessing the effects of interventions5,6 and of infectious
diseases.7
In this paper, we aim to redress the balance by showing that there
is a need to assess mechanistic studies explicitly and systematically
when interrogating the effects of interventions in infections with cor-
onaviruses. Indeed, this need is particularly urgent in diseases such as
SARS, MERS, and COVID-19 (due respectively to SARS-CoV-1,
MERS-CoV, and SARS-CoV-2), because outbreaks are rapid, limiting
the opportunity to conduct high-quality RCTs. Thus, association stud-
ies on their own tend to provide evidence that is too weak to estab-
lish causation. When rapid outbreaks are coupled with severe disease,
effective interventions need to be identified very quickly. In these cir-
cumstances, only by considering mechanistic studies alongside associ-
ation studies is it possible to build an evidence base that distinguishes
those interventions that are effective from those that are ineffective.
In the following sections, we provide several examples of the
importance of mechanistic evidence to coronavirus research. The
assessment of combination therapy for MERS highlights the difficul-
ties that can be encountered when suggesting treatments on the basis
of poor mechanistic reasoning (Section 2). That treatment for hyper-
tension is a risk factor for severe disease in the case of SARS-CoV-2
suggests that altering hypertension treatment might alleviate disease,
but the mechanisms are complex, and it is essential to consider and
evaluate more than one mechanistic hypothesis (Section 3). To suc-
cessfully limit the spread of an infection, public health interventions
need to take account of all relevant social mechanisms, rather than
just targeting risk factors. Moreover, interventions shown to be effec-
tive in one country cannot be successfully extrapolated to other coun-
tries unless the relevant social mechanisms are sufficiently similar, and
this also calls for scrutiny of mechanistic evidence (Section 4). Finally,
if vaccination programmes are to be effective, they must be carefully
tailored to the social context; again, mechanistic evidence is crucial
(Section 5). We conclude that coronavirus research is best situated
within the EBM+ evaluation framework (Section 6).
2 | COMBINATION THERAPY FOR MERS
One strategy in seeking interventions for diseases caused by novel
viruses is to repurpose existing drugs. This strategy makes much use
of evidence from mechanistic studies: evidence that the drug has
some action against the novel virus in the laboratory, both in vitro and
in vivo in experimental animals, is used to justify the decision to use
the treatment clinically. COVID-19 is no different. For example, the
antimalarial drug hydroxychloroquine inhibits SARS-CoV-2 replication
in vitro,8 leading to the suggestion that it would be a good interven-
tion for COVID-19. The motivation for this strategy is twofold.
F IGURE 1 Evidential relationships for establishing a causal claim.3
The existence of an appropriate correlation and an appropriate
mechanism together confirm causation—it is not enough to have one
without the other. Arrows signify potential positive or negative
evidential relationships
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Because of the novelty of the virus, there are no disease-specific
drugs ready for testing. And as a result of the intensity of the disease,
there is a pragmatic motivation for using compounds that may not yet
have been rigorously tested. The end goal in the standard approach is
still testing of compounds in randomized trials. However, high-quality
trials are time-consuming. Responses to COVID-19 thus rely heavily
on the use of evidence from mechanistic studies.
Can this strategy be improved by taking an EBM+ approach?
Standard EBM says little about the role mechanistic reasoning can
play in attempts to identify effective treatments. As a result, mistakes
may be made in how such evidence is handled. On the other hand,
EBM+ takes mechanistic studies into account and offers explicit guid-
ance regarding their evaluation. The following analysis of the way
repurposing was carried out in response to MERS shows how the
EBM+ approach uses mechanistic reasoning to identify effectiveness.
As a repurposing strategy, a combination of an interferon (IFN)
and ribavirin has been suggested for treating MERS. The mechanism
of action of IFN is fairly well known,9 and there was some evidence
that replication of MERS-CoV is inhibited by IFN in vitro and in
vivo10,11. A major problem for the use of IFN was that it only inhibited
the virus at clinically unobtainable concentrations. However, a syner-
gistic effect was observed by using it in combination with ribavirin, in
vitro inhibition of MERS-CoV being observed at clinically obtainable
concentrations of both compounds.12,13 Moreover, rhesus macaques
infected with MERS-CoV displayed signs of recovery when given
combination therapy.14 At no point did these studies establish that
this treatment would be effective, but this evidence nevertheless pro-
vided the motivation for clinical use of combination therapy.
The problem here is that merely having some evidence from
mechanistic studies is not enough to conclude that a mechanism of
action exists. Arguably, for a treatment to be put forward for clinical
use, the existence of a mechanism linking the treatment and recovery
from the disease must be very plausible. However, evidence that a
drug inhibits viral replication in vitro is only weak evidence that it will
inhibit viral replication in vivo. Evaluating the extent to which mecha-
nistic studies confirm the plausibility of mechanistic hypotheses is
something that EBM+ adds to standard EBM.
Demonstration of inhibition of viral replication in vitro and in vivo
in animals is not enough to conclude that the mechanism is relevant
to the clinical outcome in humans for the following reasons. In addi-
tion to viral replication, the pathology of MERS may include a mecha-
nism by which the immune system contributes to lung damage, even
after viral load is reduced.15 Reductions in lung pathology in rhesus
macaques supported combination therapy; hence, one might be
tempted to say that there is evidence for both important features of
the mechanism by which combination therapy affects outcomes in
MERS. The problem with this conclusion is that rhesus macaques are
inappropriate animals for investigating whether an intervention can
reduce respiratory pathology. This is because they only develop a mild
form of MERS that lacks the kind of severe lung damage observed
clinically.16 Full evaluation of this evidence thus shows that it is only
moderately plausible that a mechanism exists linking combination
therapy and recovery from MERS in humans.
Of course, it will be no surprise to proponents of EBM that evi-
dence from mechanistic studies may struggle to prove the existence
of a relevant mechanism. However, it is not enough merely to note
that results are not easily extrapolated from cell cultures or animals to
humans, and to apply this scepticism rigidly to all experimental sys-
tems. Common marmosets, for example, develop a form of MERS very
similar to that in humans, and evidence obtained using these animals
is much more relevant to humans than evidence from rhesus
macaques.16,17 Without explicitly evaluating mechanistic evidence, it
is not possible to distinguish a plausible (strong) mechanistic hypothe-
sis from an implausible (weak) hypothesis. Moreover, when
repurposing drugs, compounds that are more likely to be effective
should be prioritized. These considerations favour the EBM+
approach, as does an analysis of the evidence for another putative
treatment for MERS.
Mycophenolic acid was proposed as an intervention for MERS,
based on evidence that replication of MERS-CoV was inhibited in
vitro.18 Moreover, it was more efficacious than combination ther-
apy.19-21 Accordingly, mycophenolic acid was suggested as a potential
treatment for MERS and saw some clinical use.22 However,
mycophenolic acid is an immunosuppressant, and its mechanism of
action involves selective depletion of the DNA and RNA precursor
guanosine in T cells.23 Indeed, it was subsequently found to be associ-
ated with greater mortality in common marmosets.17 Testing of
mycophenolic acid should not have proceeded to clinical testing; the
immunosuppression mechanism should have been considered. EBM+
requires that the whole complex of mechanisms by which
mycophenolic acid operates should be scrutinized, rather than isolated
mechanistic hypotheses. This practice is not always followed, and in
this case, a compound made its way into clinical testing that should
not have. This is thus another case in which a full evaluation of evi-
dence from mechanistic studies would improve on the current
repurposing strategy.
3 | ANTI-HYPERTENSIVE DRUGS AND THE
INTENSITY OF COVID-19
Pharmacological risk surveillance is another area in which an eviden-
tially diverse approach to causal evaluation is desirable.24,25 Knowing
a mechanism that links a treatment and an adverse event can help
explain their observed correlation. Take, for example, antihypertensive
drugs that act on components of the renin-angiotensin system (RAS)
and might be either beneficial or harmful, as competing mechanistic
hypotheses suggest.26-28
Angiotensin converting enzyme 2 (ACE-2) is the receptor to
which SARS-CoV-2 binds to enter host cells.29,30 Some antihyperten-
sive drugs increase ACE-2 expression. It has therefore been suggested
that those drugs may worsen the intensity of COVID-19 by providing
a greater opportunity for SARS-CoV-2 to enter host cells.27 On the
other hand, ACE-2 protects against lung injury by regulating concen-
trations of angiotensin II, which is vasoconstrictive, pro-inflammatory,
and pro-oxidative.31 Hence, it has been suggested that increased
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expression of ACE-2 from using antihypertensive drugs might reduce
the intensity of COVID-19.28 This evidence suggests two mechanism
hypotheses: H1, by which the drugs increase the intensity of the dis-
ease, and H2, by which they reduce it (Figure 2).
The status of H1 and H2 is problematic. There are two separate
issues. First, the mechanistic studies from which the evidence is
obtained have not been properly evaluated, and neither has the plau-
sibility of either mechanism. The mechanism by which ACE2 protects
against lung injury (H2) is fairly well established,32,33 but the evidence
of a protective effect against SARS-CoV-2 induced lung injury34 needs
evaluation, since it may be insufficient to support the claim of a pro-
tective mechanism. For example, an error may have been committed
during the study, or the experimental system and the target system
may be dissimilar.2 Only by evaluating the evidence that supports the
proposed mechanisms can this question be settled. Secondly, these
mechanisms are plausibly not mutually exclusive. That they both oper-
ate is a distinct possibility, although if so, they probably operate in
sequence rather than in parallel: by H1, more virions enter the host
cell, and by H2, the damage caused by the virus is reduced. EBM+ rec-
ommends evaluating the whole complex of mechanisms at work.
Focusing on isolated mechanisms risks missing interactions in the way
they influence the intensity of the disease.
Despite the absence of high-quality clinical trials, we nevertheless
have some evidence of possible causal relationships. In this sort of
scenario, the EBM+ approach enables evaluation of the plausibility of
causality. We might obtain evidence of a correlation between antihy-
pertensive drug therapy and the intensity of COVID-19 through asso-
ciation studies with lower quality designs, in advance of better ones.
Such studies cannot prove causation, because they are subject to
biases. However, the EBM+ approach to causal evaluation combines
this kind of evidence with (properly evaluated) evidence of mecha-
nisms to obtain a better assessment of causality than either strand of
evidence provides alone.35 While confounding, colliding, and biases
remain problems for evidence of mere correlation between antihyper-
tensive drugs and COVID-19, if an established mechanism links the
two variables, it may be possible to regard such biases as less plausible
explanations of the observed association on COVID-19 outcomes.
This will particularly be the case when mechanistic reasoning is strong,
and sensitivity analyses suggest that no individual bias is likely to have
had a large effect. Moreover, the problem of predicting the overall
effect of H1 and H2 (and any number of other mechanisms that may
be operating on the same pathways) is resolved by establishing that
either an injurious or protective effect is correlated with antihyperten-
sive drugs, or that there is no correlation and so no overall effect. The
reinforcement of both lines of evidence, a characteristic feature of
EBM+, is thus more informative about how decisions about the use of
antihypertensive drugs during COVID-19 should be made. At the time
of writing, the evidence of association between antihypertensive
drugs and the intensity of COVID-19 is inconclusive. While at first,
studies showed an association between antihypertensives and
reduced intensity, more recent studies have found no such associa-
tion.36 But a judgement on the plausibility of causality is still better
informed by evaluating and integrating both lines of evidence.
3.1 | Strong mechanistic reasoning
The importance of mechanistic reasoning to conclusions about the
effects of antihypertensive drugs depends on the extent to which
mechanistic studies shed light on the relevant mechanisms. For mech-
anistic reasoning to be strong, key features of the mechanism complex
should be well established, and this can be achieved by meeting the
following conditions:
• Ideally, the operation of each feature should have been demon-
strated in vitro in different types of relevant cells/tissues/organ,
and in vivo in a range of species. When the experimental system
differs from the target system (eg, a macaque model investigating a
treatment in humans), a mechanism that exists in one experimental
species and not another is unlikely to be helpful.
• Such demonstrations should include evidence that the mechanism
exists, that enhancing it leads to measurable outcomes, and like-
wise for inhibiting it or abolishing it.
F IGURE 2 Two conflicting hypotheses about whether to
recommend continuing treatment with antihypertensive drugs in the
context of COVID-19. The two hypotheses interpret increased
activity of the renin-angiotensin system (RAS) in different ways,
leading to different pieces of advice regarding continuation of
antihypertensive drug use (see Aronson and Ferner)2
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• Such demonstrations should involve different ways of doing this
(eg, different agonists and antagonists, and genetic knock-outs),
and dose responsiveness should be demonstrated at concentra-
tions that could plausibly occur in vivo.
Other criteria that, if fulfilled, would strengthen the mechanistic
reasoning further include:
• Demonstrating the anatomical location of the mechanism and its
relevance. Do strategic lesions cause predictable changes?
• Demonstrating the time course of the mechanism. Does it change
in response to interventions such as upregulation or
downregulation?
• Do genetic polymorphisms,37-39 physiological variables, diseases,
and drug interactions alter it predictably?
• When any changes occur, is dose-responsiveness maintained?
Establishing key features of the whole complex of relevant mech-
anisms through a variety of experimental sources thus makes mecha-
nistic reasoning strong.
4 | MECHANISMS BEYOND THE
MICROBIOLOGICAL
Many public health interventions attempt to change or influence
human behaviour. For decades, most of this effort has gone into
preventing non-communicable diseases—for example, by preventing
smoking, obesity, and alcohol misuse and encouraging physical activ-
ity.40 Although human behaviour is also central to the transmission of
infectious disease, efforts to change behaviour have mostly been
applied to HIV, other sexually transmitted infections, and tuberculosis.
One important finding from work in non-communicable diseases,
as well as HIV, has been the realization that social and psychological
mechanisms are relevant both to aetiology and to the effectiveness of
preventive interventions.41-43 These include mechanisms linking a
behaviour change intervention and a behavioural outcome, and how
intervention content, mode of delivery, population, context, setting,
exposure, engagement, and time and place all affect efficacy and
effectiveness of interventions44,45 (eg, https://www.hum-
anbehaviourchange.org/).
A major obstacle to effective delivery of public health
programmes has been confusion between etiological mechanisms and
preventive mechanisms. The default is often to the assumption that if
we know the cause, we know how to implement prevention.41 How-
ever, knowing that there is a very strong relationship between expo-
sure to cigarette smoke and lung cancer tells you nothing about how
to help someone stop smoking. The same applies to alcohol and liver
disease or calorie consumption and obesity. Preventive mechanisms
are not the same as etiological mechanisms. This has long been recog-
nized in tobacco control, where preventive efforts have focussed on
price, advertising, availability, opportunity, addiction, and peer pres-
sure—on the mechanisms of behaviour rather than the aetiology of
the disease. Mechanisms of prevention were also the focus of early
HIV/AIDS intervention,46 but not for obesity, alcohol misuse, and
physical activity, where most efforts still focus on explaining risk or
advising caution, for example, recommending sensible alcohol
consumption.
There are important lessons here for COVID-19 in the United
Kingdom. First, the behavioural mechanisms involved in the aetiology
of the disease are the social vectors of transmission. They are com-
plex. They determine vulnerability and risk, as well as the rates at
which, and where, the disease will spread. These include mechanisms
involving family structures and interaction patterns, occupational
behaviour, urban density, housing occupation and overcrowding,
workplace and retail environment structures and organization, as well
as local social, economic, and cultural variation. However, there is
nothing in the public record or the published models of the UK Gov-
ernment that suggests that these well-known complexities were sys-
tematically built into UK models (https://www.gov.uk/government/
groups/scientific-advisory-group-for-emergencies-sage-coronavirus-
covid-19-response). Furthermore, the predictive models were initially
not only based on relatively small amounts of data but also on data
from a very different cultural environment to the United Kingdom.
The assumption that the cultures were similar enough to allow extrap-
olation is very tenuous. Above all, they were models of aetiology, not
models of prevention, exemplifying the confusion mentioned above.
Secondly, the way the population engages with preventive mea-
sures is affected by the mechanisms we are describing. So acceptance
of the measures introduced by the UK Government, such as closing
schools, giving the police new powers, and shutting pubs, restaurants,
and many workplaces (interventions that were based on the etiologi-
cal models mentioned above), will be affected by trust in government
and its messaging. Being able to act upon the specific UK Government
messaging required, for example, having space to self-isolate, reliable
digital technology and internet access in the home, effective habitual
coping skills, feelings of self-efficacy, and resources such as credit
cards or ready access to cash. Behavioural science has had a presence
at the table,47 but there is little evidence in the actions and measures
that have been put in place in the United Kingdom that the subtleties
of human behaviour mechanisms have really been integrated into the
thinking at policy level.
Thirdly, one needs to consider mechanisms that affect take-up of
interventions. The use of testing, for example, is based on the assump-
tion that people will avail themselves of the test and understand what
the result means. Not everyone will, and different individuals and
groups will respond differently to the offer. This response is governed
not only by availability, but also by the social and psychological mech-
anisms in play. The same will be true inter alia of other offers, such as
tracing apps and any vaccine, should one become available.
These mechanisms are not as well understood as we need them
to be, and there is an urgent need for programmes of research and
evidence synthesis. These mechanisms will also have to be integrated
into decision-making processes in future coronavirus pandemics. The
knowledge base, such as it is, is highly Anglo-American-centric, and its
transferability to other settings is not known. The idea that strategies
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that have been used in North America and Europe could or should be
applied elsewhere is not sound. Likewise, applying strategies that
appear to have worked in South Korea, Singapore, or China to the
United Kingdom are subject to the same uncertainty. The UK strategy
of closing schools assumed that this protects children and families,
because schools are potentially infection rich. However, this was pre-
mised on the biology of influenza, which thrives in schools, making
children vectors of infection.48 But COVID-19 is different. Children
do not appear to be at great risk from SARS-CoV-2, though their
infectivity towards adults is not clear at present. As a preventive
mechanism, school closure is a blunt instrument. When schools
reopen, various social and behavioural mechanisms come into play,
such as parents' reluctance to return their children to school, teachers'
fears of returning to work, and the need for transport to and from
schools.
Applied in settings outside the United Kingdom, this strategy is
blunter still. School closures have many potential consequences.
These include, but are not limited to, increased risks from accidents
and injury outside the relative safety of the school, sexual violence to
young girls, pressures and demands on parents, including economic
costs of staying away from work, living conditions in multiple-genera-
tion households (which, unlike schools, are likely to be important
cockpits of infection in COVID-19), long-term educational disadvan-
tages through missing schooling (more likely to damage girls), and
pressures on the social fabric to which schools contribute.49 All these
will interact with local socio-economic and cultural settings.
There are thus two strategies for jurisdictions that seek to estab-
lish public health measures to deal with coronavirus pandemics. One
is to develop local solutions, building from the ground up, rather than
naively importing solutions that may never have been understood
properly in the countries that implemented them. The other is to
extrapolate interventions that have worked well elsewhere. However,
successful extrapolation requires a detailed evaluation of the similari-
ties and differences between the relevant mechanisms in the source
and target jurisdictions.2,50 These two strategies are not mutually
exclusive and can be combined.
5 | TAILORING VACCINATION
PROGRAMMES
By June 2020, researchers worldwide haddeveloped 149 vaccine can-
didates against COVID-19, of which 17 are in clinicalevaluation and
132 in preclinical evaluation. Although the development of an effec-
tive vaccine will mark a major step forward, the mere existence of a
vaccine will not ensure high uptake.
As noted in the “Tailoring Immunization Programmes” guide publi-
shed by the WHO's Regional Office for Europe, mechanistic studies
are crucial in order to understand the psychological, contextual, and
social mechanisms that influence vaccination behaviours.51 In recent
years, several vaccination studies have investigated barriers to vacci-
nation, and have identified evidence, which confirms general mecha-
nisms that appear to work in diverse situations, as well as more
specific mechanisms that work only in particular contexts.52 Most of
these mechanistic studies can provide useful insights for coronavirus
vaccination and the assessment of its effects.
Some evidence, for instance, supports a behavioural mechanism
known as the “intention-behaviour gap,”53 which seems to work in
various contexts. Sheeran and Webb51 observed that even though
the intention to perform a behaviour and the behaviour itself are
strongly correlated, manipulating the intention will not necessarily
change behaviour. On the contrary, the authors argued that changes
in intention generally do not immediately translate into behavioural
changes. For instance, Smith et al54 reported that in the United King-
dom, at the end of the 2015 to 2016 vaccination campaign, over 70%
of parents decided to vaccinate their children against seasonal flu, but
only 53% progressed to vaccination. Sheeran and Webb53 identified
several components of this “intention-behaviour gap,” including for-
getfulness, lapse in willpower, and procrastination, and this mechanis-
tic discussion has helped policymakers to understand why some
programmes did not work as predicted, and how to improve vaccina-
tion uptake.52
Not all of these mechanisms are equally important, nor do they
function in the same way across contexts. Many studies have
reported that the prevalence of some mechanisms that inhibit or pro-
mote vaccination behaviours differ between and within countries. For
example, anti-vaccine sentiment and its related behaviours appear to
be more prevalent in high-income than in low- and middle-income
countries.55
It follows that identification of the psychological, contextual, and
social mechanisms that influence vaccine-related behaviours is not
only important in understanding why vaccination coverage is lower
than expected, but is also crucial in developing new effective vaccina-
tion programmes. This consideration is even more relevant, when, as
in the case of the COVID-19 outbreak, it may not be possible to carry
out large extended trials to test the effects of an intervention, and the
limited correlational data available from impact evaluations cannot
rule out the risk of bias. Systematically scrutinizing mechanistic stud-
ies can help policy makers to develop effective vaccination
programmes in at least two different ways.
On the one hand, knowing that a mechanism operates in the tar-
get context helps policymakers avoid problems of external validity.
For example, educational programmes aimed at increasing childhood
vaccine uptake were reported to be effective in low-income countries,
where access to vaccination-related information is difficult and paren-
tal knowledge is poor. However, similar programmes that focussed on
parents with little knowledge about vaccines in high-income countries
did not show the same effect.56 Researchers argued that this differ-
ence was due not only to different levels of knowledge in the target
populations, but also to different causes of educational barriers. While
access to information is the main problem in low-income countries,
educational barriers to immunization in high-income countries are
often associated with beliefs about safety or importance, which in
turn influence parents' decisions not to seek information.57,58
On the other hand, identifying psychological, contextual, and
social mechanisms can help policymakers to select the factors to
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target in vaccination programmes (Figure 3). For instance, the United
Kingdom and other countries have recently emphasized the impor-
tance of herd immunity, and in these countries, it might appear sensi-
ble to develop programmes that promote vaccination by highlighting
the altruistic nature of vaccination. There is, however, conflicting evi-
dence about how a sense of altruism affects vaccine behaviours.
While some studies have shown that understanding the benefits of
herd immunity could increase vaccination uptake because people
comprehend the altruistic nature of their behaviour,59,60 others have
shown that such knowledge can promote behaviours based on the
view that as more people are vaccinated, individuals get less benefit
from vaccination.61,62 Awareness that the mechanisms that determine
motivations for vaccination are complex has led some scientists to
focus more on potential interventions to bridge the “intention-behav-
iour gap.” Rather than aiming at influencing people's motivations for
vaccination, such interventions focus on keeping intentions on peo-
ple's minds and eliminating real or perceived barriers that might make
taking action difficult for some individuals.63
F IGURE 3 Factors that can influence vaccination status, motivated by EBM+ and the WHO's Tailoring Immunization Programmes.49
Personal, external, and environmental determinants influence belief and behavioural factors, which then bring about different phenomena
relevant to vaccination status
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In sum, the explicit and systematic assessment of mechanistic
studies is essential for the development of effective vaccination pro-
grams in a given context.
6 | SUMMARY AND RECOMMENDATIONS
We have presented a range of contexts in coronavirus research in which
it is beneficial to systematically assess mechanistic studies alongside
association studies. The cases we have discussed are illustrative rather
than exhaustive. Indeed, we have not touched on assessment of medical
devices, for which mechanistic reasoning is clearly essential; for example,
the use of less invasive respiratory devices64 might be viewed as an early
success of mechanistic reasoning in the COVID-19 outbreak. (Although
we have presented some considerations that bear on how mechanistic
studies should be assessed, we refer the reader to Parkkinen et al,2 who
provide a general account of EBM+ assessment, for more detail).
In the course of a coronavirus outbreak, it is essential to give neither
too little weight nor too much weight to mechanistic reasoning. On the
one hand, demanding high-quality association studies, which usually do
not exist in the early stages of an outbreak of a novel virus, can lead to
inaction and many lives lost—lives that could be saved by considering the
evidence base as a whole, which might warrant the use of particular
interventions. On the other hand, advocating interventions solely on the
basis of mechanistic reasoning that is of low quality can lead to a prolifer-
ation of ineffective interventions or ineffective extrapolations of inter-
ventions that are effective elsewhere. Thus, it is vital that mechanistic
studies and mechanistic hypotheses are explicitly and systematically eval-
uated alongside association studies.
The relevant mechanism complexes typically involve social and psy-
chological pathways, in addition to biomedical pathways. Social and psy-
chological factors are key to uptake of and adherence to an intervention.
Moreover, social behaviours can change radically during an epidemic,
partly in response to perceptions about the organism and its effects and
partly in response to public health interventions. Only by explicitly articu-
lating and systematically assessing these potential mechanisms can one
ensure that coronavirus interventions are effective.
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